Explore the latest scientific research on peptides, from healing compounds to cognitive enhancers. Evidence-based articles written for researchers and enthusiasts.
Comprehensive reviews of the latest peptide research findings
Your body is accumulating cells that refuse to die and refuse to do their jobs — secreting inflammatory signals that accelerate aging across every organ. FOXO4-DRI is the precision peptide engineered to eliminate them. Here's what eight years of research actually shows.
Eli Lilly's orforglipron could become the first non-peptide oral GLP-1 drug approved by the FDA. With a PDUFA date of April 2026, NEJM-published Phase 3 data showing 11.2% weight loss, and head-to-head superiority over oral semaglutide, here's what the clinical evidence actually says — and why a small molecule beating peptides at their own game matters more than you think.
Discover peptide research organized by function and application
Peptides studied for tissue repair, wound healing, and regenerative properties. This category covers research on compounds that may support the body's natural healing processes.
GH-releasing peptides and secretagogues research. Explore studies on peptides that interact with growth hormone pathways and their potential applications.
Nootropic and brain-supportive peptides. Research on compounds studied for their potential effects on memory, focus, and neuroprotection.
Peptides studied for metabolic function, weight management, and energy regulation. Includes research on compounds affecting metabolism and body composition.
Comprehensive information on research peptides with molecular data
Mounjaro, Zepbound, LY3298176
The first FDA-approved dual GIP/GLP-1 receptor agonist, producing record-breaking weight loss results. Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Ozempic, Wegovy, Rybelsus
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most effective medications for weight loss, available as once-weekly injection or daily oral tablet.
Body Protection Compound-157 (Pentadecapeptide)
A synthetic 15-amino acid peptide derived from human gastric juice protein, extensively studied for tissue healing, gastrointestinal protection, and regenerative properties. One of the most researched peptides in regenerative medicine.
Thymosin Beta-4
A synthetic peptide derived from the active region of Thymosin Beta-4, widely researched for tissue repair, wound healing, and recovery. TB-500 is one of the most popular healing peptides in research communities.
Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist that works in the brain to enhance sexual desire and arousal. Marketed as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Ipamorelin Acetate
A highly selective growth hormone releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol and prolactin. Known for its clean side effect profile and synergy with GHRH analogs.
Stay up to date with the newest research
Your body is accumulating cells that refuse to die and refuse to do their jobs — secreting inflammatory signals that accelerate aging across every organ. FOXO4-DRI is the precision peptide engineered to eliminate them. Here's what eight years of research actually shows.
Eli Lilly's orforglipron could become the first non-peptide oral GLP-1 drug approved by the FDA. With a PDUFA date of April 2026, NEJM-published Phase 3 data showing 11.2% weight loss, and head-to-head superiority over oral semaglutide, here's what the clinical evidence actually says — and why a small molecule beating peptides at their own game matters more than you think.
In February 2026, HHS Secretary RFK Jr. announced that 14 peptides—including BPC-157, Thymosin Alpha-1, and CJC-1295/Ipamorelin—would return to legal compounding status. Here's what changed, what didn't, and what it means for the peptide community going forward.
Novo Nordisk's CagriSema pairs an amylin analog with semaglutide to attack appetite from two directions at once. With 22.7% weight loss in Phase 3, an FDA filing already submitted, and a dramatic head-to-head showdown against tirzepatide, here's what the clinical data actually shows.
Our team continuously reviews and synthesizes the latest scientific literature to bring you accurate, up-to-date information on peptide research.